Scholarlink

Background <p>The sFlt-1/PlGF (soluble fms-like tyrosine kinase-1/placental growth factor) ratio in serum of pregnant women is a predictive marker for preeclampsia (PE). PE is often associated with intrauterine growth restriction (IUGR). Overall, growth-restricted fetuses are at increased risk for neonatal morbidities and perinatal death. An increased sFlt-1/PlGF ratio may be valuable for discriminating between different causes of IUGR. The goal of this study is to investigate the added value of the sFlt-1/PlGF ratio in pregnant women with IUGR on adverse pregnancy outcomes, neonatal morbidities and mortality.</p> Methods <p>This was a retrospective, monocenter, observational study conducted at the University Hospital of Antwerp. All singleton pregnancies with IUGR and known serum levels of sFlt-1/PlGF with a gestational age of 24 weeks until 37 weeks were included. The results were analyzed over a period of almost three years (January 2022 until October 2024). In total, 85 patients met the inclusion criteria, ten of whom had not raised serum levels of sFlt-1/PlGF (values less than 85), whereas the other 75 patients had increased sFlt-1/PlGF ratios. The maternal characteristics, fetal and neonatal mortality rates, adverse pregnancy outcomes and neonatal morbidities of all the patients and their neonates were recorded and analyzed.</p> Results <p>In IUGR fetuses with increased maternal serum sFlt-1/PlGF ratios, aberrant ultrasonic fetal doppler, fetal demise and obstetrical diseases such as PE are more often observed. In the group of neonates from mothers with a raised sFlt-1/PlGF ratio, more neonatal morbidities, such as respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, early-onset sepsis, late-onset sepsis and retinopathy of prematurity, are observed. Nevertheless, it is important to correct those results for GA and birth weight since morbidities are more often observed in more premature neonates.</p> Conclusion <p>In patients with IUGR due to placental insufficiency, an increased sFlt-1/PlGF ratio is observed. Only in the group with an increased sFlt-1/PlGF ratio did intrauterine fetal death occur. During pregnancy, more obstetrical diseases and a greater need for medication were observed. Neonatal outcomes always need to be corrected for GA and birth weight, but therefore, the inclusion number was too low.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The added value of the sFlt-1/PlGF ratio in pregnant women with intrauterine growth restriction (IUGR) with or without preeclampsia on adverse pregnancy outcomes and neonatal morbidities: a retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月30日

查看全文
  • Lieselot Arnouts,
  • Janne Terwingen,
  • Karlijn Van Damme,
  • Dominique Mannaerts

摘要

Background

The sFlt-1/PlGF (soluble fms-like tyrosine kinase-1/placental growth factor) ratio in serum of pregnant women is a predictive marker for preeclampsia (PE). PE is often associated with intrauterine growth restriction (IUGR). Overall, growth-restricted fetuses are at increased risk for neonatal morbidities and perinatal death. An increased sFlt-1/PlGF ratio may be valuable for discriminating between different causes of IUGR. The goal of this study is to investigate the added value of the sFlt-1/PlGF ratio in pregnant women with IUGR on adverse pregnancy outcomes, neonatal morbidities and mortality.

Methods

This was a retrospective, monocenter, observational study conducted at the University Hospital of Antwerp. All singleton pregnancies with IUGR and known serum levels of sFlt-1/PlGF with a gestational age of 24 weeks until 37 weeks were included. The results were analyzed over a period of almost three years (January 2022 until October 2024). In total, 85 patients met the inclusion criteria, ten of whom had not raised serum levels of sFlt-1/PlGF (values less than 85), whereas the other 75 patients had increased sFlt-1/PlGF ratios. The maternal characteristics, fetal and neonatal mortality rates, adverse pregnancy outcomes and neonatal morbidities of all the patients and their neonates were recorded and analyzed.

Results

In IUGR fetuses with increased maternal serum sFlt-1/PlGF ratios, aberrant ultrasonic fetal doppler, fetal demise and obstetrical diseases such as PE are more often observed. In the group of neonates from mothers with a raised sFlt-1/PlGF ratio, more neonatal morbidities, such as respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, early-onset sepsis, late-onset sepsis and retinopathy of prematurity, are observed. Nevertheless, it is important to correct those results for GA and birth weight since morbidities are more often observed in more premature neonates.

Conclusion

In patients with IUGR due to placental insufficiency, an increased sFlt-1/PlGF ratio is observed. Only in the group with an increased sFlt-1/PlGF ratio did intrauterine fetal death occur. During pregnancy, more obstetrical diseases and a greater need for medication were observed. Neonatal outcomes always need to be corrected for GA and birth weight, but therefore, the inclusion number was too low.